{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nab-sirolimus", "query": { "intervention": "nab-sirolimus" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nab-sirolimus&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T02:48:55.422Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03190174", "title": "Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ewing Sarcoma", "PEComa", "Epithelioid Sarcoma", "Desmoid Tumor", "Chordoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Classical Hodgkin Lymphoma", "Colorectal Cancer", "MTOR Activating Mutation" ], "interventions": [ { "name": "Nab-Rapamycin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sarcoma Oncology Research Center, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 34, "start_date": "2017-08-24", "completion_date": "2021-12-02", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190174" }, { "nct_id": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Anatomic Stage IV Breast Cancer AJCC v8", "Anemia", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Castration-Resistant Prostate Carcinoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid System Neoplasm", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Primary Myelofibrosis", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Myeloproliferative Neoplasm", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Myelodysplastic Syndrome", "Refractory Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Primary Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dacomitinib", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Tretinoin", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 2, "start_date": "2020-04-01", "completion_date": "2020-12-10", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878524" }, { "nct_id": "NCT04229004", "title": "A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Gemcitabine combined with nab-paclitaxel", "type": "DRUG" }, { "name": "Dose -mFOLFIRINOX", "type": "DRUG" }, { "name": "Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel", "type": "DRUG" }, { "name": "Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "Drug: Dose -SM-88", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pancreatic Cancer Action Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 502, "start_date": "2020-01-31", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 25, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04229004" }, { "nct_id": "NCT01376310", "title": "GSK1120212 Rollover Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK1120212", "type": "DRUG" }, { "name": "Docetaxel + GSK1120212", "type": "DRUG" }, { "name": "Erlotinib + GSK1120212", "type": "DRUG" }, { "name": "Pemetrexed + GSK1120212", "type": "DRUG" }, { "name": "Carboplatin + GSK1120212", "type": "DRUG" }, { "name": "Nab-paclitaxel + GSK1120212", "type": "DRUG" }, { "name": "Gemcitabine + GSK1120212", "type": "DRUG" }, { "name": "Everolimus + GSK1120212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2010-11-02", "completion_date": "2018-01-18", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 13, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01376310" }, { "nct_id": "NCT05661461", "title": "Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor, Solid", "Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2022-11-23", "completion_date": "2026-08-01", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 2, "location_summary": "San Antonio, Texas • West Valley City, Utah", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05661461" }, { "nct_id": "NCT06308419", "title": "A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leiomyosarcoma", "Soft-tissue Sarcomas" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2024-08-14", "completion_date": "2031-02-01", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06308419" }, { "nct_id": "NCT03439462", "title": "Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 60, "start_date": "2018-07-01", "completion_date": "2022-08-26", "has_results": true, "last_update_posted_date": "2024-01-02", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439462" }, { "nct_id": "NCT02587325", "title": "Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Hypertension" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-04-01", "completion_date": "2022-09-16", "has_results": true, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 6, "location_summary": "Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Torrance", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02587325" }, { "nct_id": "NCT05997017", "title": "Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Endometrioid Tumor", "Cancer", "Tumor", "Recurrent Endometrial Carcinoma", "Endometrioid Endometrial Cancer" ], "interventions": [ { "name": "nab-sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aadi Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2023-12-28", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • Miami Beach, Florida • Las Vegas, Nevada + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05997017" }, { "nct_id": "NCT00635284", "title": "ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ABI-009", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2007-12-01", "completion_date": "2011-06-01", "has_results": false, "last_update_posted_date": "2019-10-18", "last_synced_at": "2026-09-03T02:48:55.422Z", "location_count": 2, "location_summary": "Santa Monica, California • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00635284" } ] }